Evoke Pharma Inc Stock Price, News & Analysis

Evoke Pharma and EVERSANA received the Sales Aid Silver Award for their "Spray Away" campaign promoting GIMOTI, a nasal spray for Diabetic Gastroparesis, at the PM360 Trailblazer Initiative Awards held on September 23, 2021. The campaign highlights GIMOTI's innovative delivery method, aiding patients who struggle with oral medications due to nausea or gastric delay. Since launching GIMOTI in October 2020, Evoke has achieved nearly 9 million media impressions and continues to enhance awareness among healthcare providers and patients.

Evoke Pharma, Inc. (NASDAQ: EVOK) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. CEO Dave Gonyer and CBO Matt D’Onofrio will engage in a virtual presentation on September 13, which will be available on-demand starting at 7:00 am ET.

This conference will include corporate presentations and one-on-one meetings. Interested investors can schedule calls with Evoke management via their H.C. Wainwright representative.

Evoke Pharma reported a 162% increase in product sales and 152% growth in prescriptions for Gimoti in Q2 2021. The company expanded its base of new prescribers significantly, with a rise from 84 to 132 over the quarter. Net loss decreased to approximately $2.3 million from $7.0 million year-over-year, while net product sales reached $237,000. Total operating expenses were $2.4 million, down from $7.0 million in Q2 2020. As of June 30, 2021, cash equivalents stood at $16.7 million, expected to support operations until Q3 2022.

Evoke Pharma, Inc. (Nasdaq: EVOK), focused on GI treatments, will release its Q2 2021 financial results on August 12, 2021, post-market. A conference call will follow at 4:30 p.m. ET to discuss the results, with dial-in numbers provided for domestic and international participants. The company is known for GIMOTI^®, a nasal spray for diabetic gastroparesis, the only FDA-approved treatment in the U.S. for this condition. Evoke cautions that forward-looking statements may not guarantee future results due to various risks, including reliance on GIMOTI and potential disruptions from COVID-19.

Evoke Pharma (NASDAQ: EVOK) and EVERSANA have announced their support for Gastroparesis Awareness Month through sponsorship of the upcoming Digestive Health Virtual Walk by the International Foundation for Gastrointestinal Disorders. This collaborative effort aims to raise awareness about gastroparesis and promote community education regarding its diagnosis and management. The virtual walk runs from August 21 to September 4, 2021, allowing participants to engage at their own pace. Evoke has also established the EvokeAssist program to aid patients affected by diabetic gastroparesis.

Evoke Pharma, focusing on gastrointestinal diseases, announced marketing initiatives for GIMOTI, its nasal spray for diabetic gastroparesis (DGP). The program aims to increase awareness and trial among healthcare providers by providing samples primarily to gastroenterologists and advanced practice practitioners. A recent study indicated that 20-40% of DGP patients struggle with oral medication absorption, leading to significant interest from physicians in prescribing GIMOTI. Evoke hopes this initiative will enhance access to its treatment for those with DGP.

Evoke Pharma has announced its membership in the International Foundation for Gastrointestinal Disorders (IFFGD) Industry Council, aiming to enhance support for patients with diabetic gastroparesis. This membership allows Evoke to participate in biannual meetings focused on industry insights. Additionally, Evoke will sponsor the IFFGD’s 30th Anniversary Digestive Health Virtual Walk in August 2021, aiming for participants to collectively walk 10,950 miles as part of Gastroparesis Awareness Month. This initiative highlights the significant unmet medical need for new treatments in this area.

Evoke Pharma (NASDAQ: EVOK) reports positive findings from a recent market research study on GIMOTI (metoclopramide) nasal spray. Conducted by EVERSANA, the study reveals an 81% intent to prescribe GIMOTI, up from previous figures, including 90% among targeted gastroenterologists. Awareness of GIMOTI has also risen significantly, with 46% of targeted GIs reporting high awareness. The data suggests that GIMOTI is increasingly recognized as an effective treatment for diabetic gastroparesis. Evoke anticipates further discussion on these findings at the upcoming GI ReConnect Conference.

Evoke Pharma announced that its patent No. 11,020,361 for Gimoti (metoclopramide) nasal spray is now listed in the FDA's Orange Book, enhancing intellectual property protection. Gimoti is FDA-approved for treating symptoms of acute and recurrent diabetic gastroparesis and is the first non-oral option available for this condition. The new patent extends protection until at least 2029. President David Gonyer expressed confidence in Gimoti's potential to improve patient quality of life by offering a unique treatment method.